Loading
Biologist and long-time CNIO director of biotechnology programmes who became Acting Scientific Director of Spain's national cancer research centre in 2025.
Fernando Peláez is Acting Scientific Director of the Centro Nacional de Investigaciones Oncológicas (CNIO) in Madrid, following the 2025 departure of María Blasco. A biologist with a background in natural-products drug discovery, he previously directed CNIO's Biotechnology Programme. In September 2025 the CNIO Board of Trustees proposed Raúl Rabadán as the centre's next Scientific Director, with Peláez holding the acting role in the interim.
| Title | Journal | Year |
|---|---|---|
| Platensimycin is a selective FabF inhibitor with potent antibiotic properties Europe PMC author record matched by affiliation (Merck Sharp & Dohme research centre, Madrid, before CNIO) | Nature | 2006 |
| Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties Europe PMC author record matched by affiliation (Merck Sharp & Dohme research centre, Madrid, before CNIO) | Proceedings of the National Academy of Sciences | 2007 |
| Discovery of a small molecule insulin mimetic with antidiabetic activity in mice Europe PMC author record matched by affiliation (Merck Sharp & Dohme research centre, Madrid, before CNIO) | Science | 1999 |
Shares the tags leadership, basic science.
Shares Proceedings of the National Academy of Sciences and the tag leadership.
Shares Proceedings of the National Academy of Sciences and the tag leadership.
Shares Proceedings of the National Academy of Sciences and the tag leadership.
Shares Science and the tag leadership.
Shares Nature and the tag leadership.
Shares Nature and the tag leadership.